As the eldest in the seven-piece K-pop supergroup, Jin was the first group member of BTS to return to the public eye in June 2024 following the completion of his 18-month mandatory military service.

Zydus Wellness Ltd has informed BSE regarding Intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure<BR>Requirements) Regulations 2015 (the Listing Regulations) ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Zydus Lifesciences: The pharmaceutical company announced the USFDA orphan drug designation to Usnoflast for the treatment of amyotrophic lateral sclerosis. Agro Tech Foods: The CCI approved the ...

Zydus Lifesciences Ltd. said on Wednesday that the US Food and Drug Administration granted its underdevelopment drug Usnoflast the orphan drug designation, according to an exchange filing on Wednesday ...

“This Orphan Drug Designation from the USFDA underlines the urgent need to develop Usnoflast to address Amyotrophic Lateral Sclerosis (ALS), which is a fatal neurodegenerative disease," said Zydus' ...

Also: Everything announced at Samsung Unpacked 2025 The features provide a more personalized approach to wellness, from health coaches that provide recommendations based on the data gathered to ...

The city on Wednesday will officially launch what it is calling a “neighborhood wellness court” in Kensington, an initiative in which police will arrest people who are openly using drugs, issue them ...

It’s not too late! Every year, millions around the world pledge to abstain from alcohol in a challenge known as Dry January. Taking a break from booze can improve your physical and mental well ...

Of course, some criticize these modern logos as being copy-and-paste, minimalist and unoriginal. Those yearn to return to the unique logos of the 1990s and early 2000s, where the NFL used elements ...

Credit: David Herraez Calzada / Shutterstock. The US Food and Drug Administration (FDA) has granted approval for Zydus Lifesciences to proceed with a randomised Phase IIb trial of its oral NLRP3 ...